Tenax Therapeutics: Some Future Potential
Source: SeekingAlpha
2026-02-26 14:07:37 ET
Shares of cardiopulmonary concern Tenax Therapeutics, Inc. ( TENX ) have roughly doubled since providing a corporate update and presenting with key opinion leaders on November 13, 2025. The company addressed its rationale for advancing oral levosimendan (TNX-103) against pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). With a pivotal readout expected in 2H26, a PH-HFpEF indication comprising ~1.4 million patients domestically, and no approved therapies, the recent insider buying in Tenax merited a deeper dive. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Tenax Therapeutics: Some Future Potential
Merck & Company Inc.
NASDAQ: MRK
MRK Trading
-0.73% G/L:
$121.84 Last:
2,790,061 Volume:
$122.96 Open:
MRK Latest News
April 02, 2026 06:50:00 am
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
MRK Stock Data
$291,612,827,755
2,457,202,311
0.02%
2165
N/A
Pharmaceuticals
Healthcare
US
Rahway
